Denis Soulieres, The Université de Montréal, Montréal, Canada, describes recent advances in the development of predicative biomarkers for head and neck cancers that test beyond PD-L1. Whilst there will be novel biomarker data from the Phase III KEYNOTE-040 (NCT02252042) and KEYNOTE-048 (NCT02358031) trials that will soon be released, current biomarkers tend to be more prognostic than predicative of responses in patients. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

свернуть